Real-World Practice Patterns for Prevention and Management of Potential Adverse Events with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

INTRODUCTION: Pirfenidone is an oral antifibrotic agent approved for idiopathic pulmonary fibrosis (IPF). Real-world data on adverse event (AE) management for pirfenidone are limited. Strategies for managing potential antifibrotic therapy AEs were examined in a sample of US pulmonologists. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Wencel, Mark L., Haselkorn, Tmirah, Limb, Susan L., Stauffer, John L., Morgenthien, Elizabeth, Raimundo, Karina, LaCamera, Peter P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare Communications 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967051/
https://www.ncbi.nlm.nih.gov/pubmed/32026247
http://dx.doi.org/10.1007/s41030-018-0056-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967051/
https://www.ncbi.nlm.nih.gov/pubmed/32026247
http://dx.doi.org/10.1007/s41030-018-0056-8

Ejemplares similares